Abstract:The overactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signal transduction pathway has been examined in various carcinomas and is reported to be significantly correlated with prognosis. However, little is known with regard to the PI3K/Akt signal transduction pathway in advanced non-small cell lung carcinoma (NSCLC). The present study investigated the expression of PI3K and phosphorylated (p)-Akt protein and its clinical significance in NSCLC. The clinical records of 157 patients with NSCLC (70 stage I-IIIA and 87 stage IIIB-IV cases), consisting of 75 cases of squamous cell carcinoma and 82 cases of adenocarcinoma, together with 30 resected lung cancer tumor-adjacent tissue samples, were retrospectively evaluated. PI3K and p-Akt expression in the NSCLC and tumor-adjacent tissues were measured using an immunohistochemical method, and its correlation with the clinicopathological data and prognosis in advanced NSCLC was evaluated. PI3K and p-Akt expression was significantly higher in the cancer tissues (chi(2)=14.8455; P=0.001) than in the tumor-adjacent tissues (chi(2)=14.2615; P=0.001). The overexpression of p-Akt in stage I-IIIA NSCLC was associated with lymph node metastasis (chi(2)=6.1189; P=0.013) and tumor-node-metastasis (TNM) stage (chi(2)=8.9752; P=0.011), however, no correlation was observed with gender, age, pathological type and histological grade. The overexpression of p-Akt in stage IIIB-IV NSCLC was only associated with TNM stage (chi(2)=5.7501; P=0.016), and no correlation was observed with gender, age, Pathological type, histological grade and Eastern Cooperative Oncology Group (ECOG) performance status (PS). The overexpression of PI3K was not found to correlate with the aforementioned clinicopathological variables in all patients. Survival was significantly improved in advanced NSCLC with PI3K- and p-Akt-negative expression compared with PI3K- and p-Akt-positive expression [P13K: 17.70 months (95% confidence interval (CI), 15.11-20.28 mont hs) vs. 13.43 months (95% CI, 11.83-15.02 months); P=0.004; and p-Akt: 17.13 months (95% CI, 14.93-19.34 months) vs. 13.07 months (95% CI, 11.32-14.82 months); P=0.007]. Multivariate analysis showed that PI3K [hazard ratio (HR)=2.143; 95% CI, 1.211-3.790; P=0.009], p-Akt (HR=1.991; 95% CI, 1.009-3.927; P=0.047), TNM stage (HR=4.788; 95% CI, 2.591-8.848; P=0.001) and ECOG-PS (HR=3.272; 95% CI, 1.701-6.296; P=0.001) were independent predictors for survival in stage IIIB-IV NSCLC. These results indicated that p-Akt overexpression closely correlates with factors of an unfavorable prognosis in NSCLC. PI3K and p-Akt overexpression are independent markers of a poor prognosis in advanced NSCLC.

PI3K/Akt/mTOR Signaling Pathway and Non-small Cell Lung Cancer

Research Progress of Mtor Signaling Pathway and Non-Small Cell Lung Cancer

Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)

Autophagy-related signaling pathways in non-small cell lung cancer

PPIP5K2 Facilitates Proliferation and Metastasis of Non-Small Lung Cancer (NSCLC) through AKT Signaling Pathway

LKB 1 / AMPK / Mtor Signaling Pathway in Non-small-cell Lung Cancer

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer

Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma

PI3K/AKT/mTOR Pathway, Hypoxia, and Glucose Metabolism: Potential Targets to Overcome Radioresistance in Small Cell Lung Cancer

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma.

Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy

SH2B1 Promotes NSCLC Cell Proliferation Through PI3K/Akt/mTOR Signaling Cascade

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers

PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer

Down-Regulation of SREBP via PI3K/AKT/mTOR Pathway Inhibits the Proliferation and Invasion of Non-Small-Cell Lung Cancer Cells

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer